// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

SINGLE CELL ANALYSIS OF SPONDYLOARTHRITIS REGULATORY T CELLS IDENTIFIES DISTINCT SYNOVIAL GENE EXPRESSION PATTERNS AND CLONAL FATES

D. Simone - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

N/A

SINGLE CENTRE EXPERIENCE OF THE CLINICAL SPECTRUM, AETIOLOGIES AND MANAGEMENT OF NON-INFECTIOUS AORTITIS

R. S. Andev - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Aortic wall inflammation

N/A

SOUTHEND PRE-TEST PROBABILITY SCORE AND HALO SCORE AS MARKERS FOR DIAGNOSIS AND MONITORING OF GCA: EARLY RESULTS FROM THE PROSPECTIVE HAS-GCA STUDY

A. Sebastian - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

STP938, A NOVEL, POTENT AND SELECTIVE INHIBITOR OF CTP SYNTHASE 1 (CTPS1) DEMONSTRATES EFFICACY IN RODENT MODELS OF INFLAMMATION AND ARTHRITIS

H. Asnagli - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

SUBCHONDRAL BONE NORMALIZATION AFTER KNEE JOINT DISTRACTION TREATMENT AS MEASURED WITH CT

M. Jansen - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

SUBSTANTIAL IMPACT OF AUTOANTIBODY ENRICHMENT ON OUTCOMES IN EARLY RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT: DATA FROM A LARGE POOLED ANALYSIS OF 4 RCTS

K. Michaud - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

SUCCESSFUL PATIENT EDUCATION ON COVID-19 VACCINE SAFETY IN A LARGE RHEUMATOLOGY COHORT USING INTERACTIVE MOBILE-PHONE VIDEO TECHNOLOGY: CONTEXT, RESULTS, AND NEXT STEPS

L. Rajagopala - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

SUMMARY OF PATIENT/PARENT ORGANISATION SERVICES PROMOTING SELF- AND SHARED-MANAGEMENT OF JIA IN THE UK AND IRELAND

S. Stones - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

SUSTAINED GUSELKUMAB RESPONSE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS THROUGH WEEK 52 OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES

C. T. Ritchlin - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

guselkumab (IV)

SWITCHING OF TREATMENT FROM REFERENCE ETANERCEPT TO SANDOZ ETANERCEPT BIOSIMILAR IN PATIENTS WITH RHEUMATIC DISEASES: AN INTERIM ANALYSIS OF REAL-WORLD DATA FROM THE COMPACT STUDY

M. Schmalzing - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Etanercept biosimilar

TARGETED METABOLOMIC PROFILING AND PREDICTION OF CARDIOVASCULAR EVENTS: A PROSPECTIVE STUDY OF PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS

K. Colaco - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Transient Ischemic Attack

N/A

TARGETED SERUM PROTEOMIC ANALYSIS FOLLOWING UPADACITINIB TREATMENT IN ANKYLOSING SPONDYLITIS SHOWS ROBUST SUPPRESSION OF INNATE AND ADAPTIVE IMMUNE PATHWAYS WITH TISSUE REPAIR MODULATION

T. Sornasse - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

ABT-494

THE 2021 DORIS DEFINITION OF REMISSION IN SLE – FINAL RECOMMENDATIONS FROM AN INTERNATIONAL TASK FORCE

R. van Vollenhoven - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

THE ARTHRITIS COMPONENT OF THE SLEDAI SHOULD ONLY BE SCORED IF THERE IS JOINT SWELLING

K. Mahmoud - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Prednisolone

THE ASSOCIATION BETWEEN BARIATRIC SURGERY AND CARPAL TUNNEL SYNDROME: A COHORT STUDY FROM SWEDISH NATIONWIDE HEALTHCARE REGISTRIES

J. Lane - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Familial carpal tunnel syndrome

N/A

THE ASSOCIATION BETWEEN BARIATRIC SURGERY AND DUPUYTREN DISEASE: A COHORT STUDY FROM SWEDISH NATIONWIDE HEALTHCARE REGISTRIES

T. Burkard - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

THE ASSOCIATION OF STIGMA WITH DISEASE VARIABLES IN PATIENTS WITH FIBROMYALGIA (FM)

M. Offenb�cher - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Fibromyalgia

Pamicogrel

THE DEVELOPMENT AND VALIDATION OF A RISK STRATIFICATION QUESTIONNAIRE TO SCREEN FOR MEDICATION RELATED OSTEONECROSIS OF THE JAW RISK IN OSTEOPOROTIC PATIENTS

Y. El-Miedany - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

THE EFFECT OF FILGOTINIB ON ENTHESITIS: 100-WEEK DATA FROM AN OPEN-LABEL EXTENSION STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

P. Helliwell - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

Filgotinib

THE EFFECT OF OSTEOARTHRITIS ON HEALTHY WORKING LIFE EXPECTANCY AT AGE 50 IN ENGLAND

M. Lynch - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Copyright © 2026. QuantiNova All rights reserved